An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL

scientific article published on 30 August 2019

An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/S41375-019-0569-7
P698PubMed publication ID31471562

P50authorSigrid S SkånlandQ58206316
Deepak B Thimiri Govinda RajQ61133617
Geir Erland TjønnfjordQ90232036
P2093author name stringKjetil Taskén
Ludvig A Munthe
Andrea Cremaschi
Johanne U Hermansen
Henrik Bendiksen
P2860cites workBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaQ26765624
The potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaQ28075504
Chronic lymphocytic leukaemiaQ30249196
National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953-2012: a systematic analysis of population-based dataQ31147343
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignanciesQ33419789
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLLQ33714712
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesQ33893704
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemiaQ34009003
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AMLQ34042250
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic LeukemiaQ35958056
Chronic lymphocytic leukemia therapy: new targeted therapies on the wayQ37113544
The B-cell receptor pathway: a critical component of healthy and malignant immune biologyQ38232484
Targeting B Cell Signaling in Chronic Lymphocytic LeukemiaQ38654101
Ibrutinib for treatment of chronic lymphocytic leukemiaQ38765015
The PI3K pathway: clinical inhibition in chronic lymphocytic leukemiaQ38797084
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activityQ39056302
Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic LeukemiaQ41848521
Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cellsQ42317487
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.Q51280033
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.Q52582128
Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia.Q54261746
Chronic lymphocytic leukaemiaQ56270980
Microenvironmental agonists generate phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCLQ56514276
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaQ57471770
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2Q58776981
Cryopreservation of primary B cells minimally influences their signaling responsesQ59792926
Targeted Therapies in CLL: Monotherapy Versus Combination ApproachesQ90395831
The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemiaQ90569013
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemiaQ91735722
Ibrutinib and Venetoclax for First-Line Treatment of CLLQ92374811
P433issue2
P921main subjectbiomarkerQ864574
ibrutinibQ5984881
P304page(s)478-487
P577publication date2019-08-30
P1433published inLeukemiaQ6534498
P1476titleAn in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL
P478volume34

Search more.